Advantage : Amycretin Development Stage# Amycretin : Phase 1b/2a completed (obesity, Lancet)
Cardiovasc Res 117(11):e138e140
Found's clinicians are trained in obesity medicine and use your MetabolicPrint Found's proprietary tool for understanding how your body processes food, responds to medication, and regulates weight to determine whether semaglutide is the right fit and to personalize your dose over time
The improved regulation of glycemia by GLP-1RA, along with their ability to reduce lipid synthesis, enhanced beta oxidation of free fatty acids and autophagy of fat cells contributes to their lipid modulation properties (59)
Turned out I was undereating protein by a lot
The Bridge program only covers obesity medications, so that pharmaceutical companies will continue to charge higher prices for GLP-1 drugs to treat diabetes